Phase 2 Randomized, Open-Label Study of Gs-5885 Administered Concomitantly With Gs-9451, Tegobuvir and Ribavirin...... Grant uri icon

total award amount

  • 23736.18

direct costs

  • 18988.94

sponsor award ID

  • GS-US-248-0120

local award ID

  • 00081951